Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ADAM (Advanced Digital Additive Manufacturing) is a biotechnology company specializing in the 3D bioprinting of personalized bone implants and other tissues. Founded in 2018, the company utilizes proprietary bioceramic and biopolymer materials to create patient-specific grafts based on MRI and CT data. Their "Technology-as-a-Service" (TaaS) model aims to provide on-demand implant production at the point of care, significantly reducing surgical planning and delivery times. Beyond bone, ADAM is researching bioprinted blood vessels, heart valves, and bronchial implants to address the global shortage of donor organs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ADAM.